Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPI-1007 for recent-onset nonarteritic anterior ischemic optic neuropathy
2015-003079-31Phase 2Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Jul 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QPI-1007 in non-arteritic anterior ischemic optic neuropathy (NAION) (2 arms), sponsored by Quark Pharmaceuticals. Primary endpoint: Loss of 15 or more ETDRS letters in best corrected visual acuity at Month 6. Started Jul 2016; status: completed.
02
Drugs
QPI-1007
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on 2015-003079-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003079-31.